RGRX OTC
RegeneRx Biopharmaceuticals, Inc.
1W: +0.0%
1M: +57.1%
3M: +83.3%
YTD: +266.7%
1Y: +450.0%
3Y: -100.0%
5Y: -100.0%
$0.00
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$77K
+0.0% ▲
5Y CAGR: +6.3%
Gross Profit
$77K
+9.5% ▲
5Y CAGR: +7.4%
Operating Income
-$1M
-5.5% ▼
Net Income
-$2M
-8.1% ▼
EPS (Diluted)
$-1.00
-7094.2% ▼
EBITDA
-$1M
-2603.2% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $70K | $77K | $77K | $77K | $77K |
| YoY Growth | +23.0% | +10.2% | -0.0% | +0.0% | +0.0% |
| Cost of Revenue | $81 | $65 | $5K | $7K | $0 |
| Gross Profit | $70K | $77K | $72K | $70K | $77K |
| Gross Margin | 99.9% | 99.9% | 93.6% | 91.4% | 100.0% |
| R&D Expenses | $81K | $65K | $5K | $7K | $0 |
| SG&A Expenses | $1M | $1M | $1M | $1M | $1M |
| Operating Expenses | $1M | $1M | $1M | $1M | $1M |
| Operating Income | -$1M | -$1M | -$1M | -$1M | -$1M |
| Operating Margin | -1899.0% | -1644.0% | -1687.1% | -1731.3% | -1826.4% |
| Interest Expense | $87K | $153K | $233K | $325K | $326K |
| Income Before Tax | -$2M | -$1M | -$2M | -$2M | -$2M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$2M | -$1M | -$2M | -$2M | -$2M |
| Net Margin | -2862.2% | -1829.0% | -1984.1% | -2081.8% | -2249.8% |
| EPS (Diluted) | $-0.02 | $-0.01 | $-0.01 | $-0.01 | $-1.00 |
| EBITDA | -$2M | -$1M | -$1M | $56K | -$1M |
| Shares Outstanding | 121M | 131M | 133M | 139M | 144M |